A. Muhs

M. Heilemann, G. Schwall, S. Liebner, 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Effects of single oral doses of lysine clonixinate and acetylsalicylic acid on platelet functions in man

A. Muhs, D. Pallapies, B. Peskar, 1996, European Journal of Clinical Pharmacology.

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

G. Kerchner, K. Scearce-Levie, I. Hötzel, 2021, Science Translational Medicine.

Engineering Amyloid-Like Assemblies from Unstructured Peptides via Site-Specific Lipid Conjugation

D. Hickman, A. Muhs, A. Pfeifer, 2014, PloS one.

Dense (aged) circulating red cells contain normal concentrations of adenosine triphosphate (ATP)

C. W. Gabel, A. Muhs, F. Kirkpatrick, 1979 .

INSIGHT INTO DESY’S TEST LABORATORY FOR NIOBIUM RAW MATERIAL AND SEMI-FINISHED PRODUCTS

A. Muhs, A. Ermakov, J. Iversen, 2019 .

Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies

L. Dinkelborg, Efthymia Vokali, D. Hickman, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

Mapping microglia states in the human brain through the integration of high-dimensional techniques

Sagar, R. Sankowski, J. Priller, 2019, Nature Neuroscience.

Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects

G. Knott, A. Muhs, B. Schneider, 2017, Scientific Reports.

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

K. Scearce-Levie, J. Ernst, J. Atwal, 2016, Cell reports.

Anticorps tau humanisé

F. Leuven, A. Muhs, O. Adolfsson, 2013 .

Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression

Hsu-hsin Chen, T. Beach, M. P. van der Brug, 2018, Scientific Reports.

Human genome–guided identification of memory-modulating drugs

T. Elbert, D. D. de Quervain, C. Gerhards, 2013, Proceedings of the National Academy of Sciences.

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

F. van Leuven, H. Devijver, D. Hickman, 2013, PloS one.

An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ

N. Toni, R. Weimer, J. Atwal, 2012, The Journal of Neuroscience.

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

M. Ultsch, C. Eigenbrot, J. Ernst, 2016, Scientific Reports.

Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β-Amyloid-42 Fibril Formation*

Thomas Schrader, Asad Jan, Andrea Pfeifer, 2012, The Journal of Biological Chemistry.

Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 Species*

P. Magistretti, H. Lashuel, A. Muhs, 2010, The Journal of Biological Chemistry.

Cell Transplantation Improves Ventricular Function After a Myocardial Infarction: A Preclinical Study of Human Unrestricted Somatic Stem Cells in a Porcine Model

D. Spitkovsky, Jun Wu, Ren-Ke Li, 2005, Circulation.

Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases*

D. Riesner, D. Hickman, C. Nicolau, 2011, The Journal of Biological Chemistry.

Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography.

B. Gulyás, C. Spenger, C. Halldin, 2012, Nuclear medicine and biology.

Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation.

A. Herrmann, J. Schrader, H. E. von der Leyen, 2003, Human gene therapy.

Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression

Hsu-hsin Chen, T. Beach, M. P. van der Brug, 2018, Scientific Reports.

Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope

F. van Leuven, H. Devijver, D. Hickman, 2016, Journal of Alzheimer's disease : JAD.

Cytosolic Ca2+ overload and macromolecule permeability of endothelial monolayers.

T. Noll, A. Muhs, H. Piper, 1992, Herz.

Status of Nb-Pb superconducting RF-GUN cavities

M. Ferrario, J. Sekutowicz, P. Kneisel, 2007, 2007 IEEE Particle Accelerator Conference (PAC).

Structure of Crenezumab Complex with A beta Shows Loss of beta-Hairpin.

M. Ultsch, C. Eigenbrot, J. Ernst, 2016 .

An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome

E. Masliah, M. Maloney, W. Mobley, 2016, PloS one.

Regulation of endothelial Na(+)-K(+)-ATPase activity by cAMP.

J. Williams, J. Schrader, M. Gruwel, 1998, Biochemical and biophysical research communications.

EFFICACY OF ACI-35, A LIPOSOMAL ANTI-PHOSPHO TAU VACCINE IN TWO DIFFERENT MOUSE MODELS OF ALZHEIMER’S DISEASE

A. Muhs, P. Colin, B. Schneider, 2016, Alzheimer's & Dementia.

Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.

N. Toni, J. Cirrito, S. Liebner, 2013, Journal of Alzheimer's disease : JAD.

A42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete

P. Magistretti, H. Lashuel, A. Muhs, 2011 .

Development of a Small D-Enantiomeric Alzheimer’s Amyloid-β Binding Peptide Ligand for Future In Vivo Imaging Applications

B. Gulyás, C. Spenger, C. Halldin, 2012, PloS one.

FIRST-IN-HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18-F PI-2620 IN ALZHEIMER’S DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS

J. Seibyl, K. Marek, L. Dinkelborg, 2017, Alzheimer's & Dementia.

Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.

N. Sreenivasachary, A. Muhs, W. Froestl, 2016, Bioorganic & medicinal chemistry letters.

QE MEASUREMENTS of a Nb-Pb SRF PHOTOINJECTOR

J. Sekutowicz, P. Kneisel, A. Muhs, 2008 .

STATUS OF THE ALL SUPERCONDUCTING GUN CAVITY AT DESY

E. Vogel, J. Sekutowicz, H. Weise, 2019 .

Photoemission tests of a Pb/Nb superconducting photoinjector

J. Sekutowicz, P. Kneisel, A. Muhs, 2007, 2007 IEEE Particle Accelerator Conference (PAC).

PRECLINICAL CHARACTERIZATION OF PI-2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES

L. Dinkelborg, D. Hickman, A. Muhs, 2017, Alzheimer's & Dementia.

Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo

J. Atwal, R. Watts, A. Muhs, 2009, Alzheimer's & Dementia.

Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β-Amyloid-42 Fibril Formation*

H. Lashuel, N. Rezaei-Ghaleh, T. Schrader, 2012, The Journal of Biological Chemistry.

CLINICAL UPDATE: 18F-PI-2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER’S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY

J. Seibyl, K. Marek, L. Dinkelborg, 2018, Alzheimer's & Dementia.